Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
Date:8/8/2013

SAN FRANCISCO, Aug. 8, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2013.

Cash and investments in marketable securities at June 30, 2013 were $226.9 million.

"I am very pleased with Nektar's performance this year," said Howard W. Robin, President and Chief Executive Officer of Nektar. "AstraZeneca has confirmed that they will be filing both the naloxegol NDA and MAA in September.  Naloxegol could be the first once-daily oral medication to treat patients with opioid-induced constipation.  In June, we announced positive data from our Human Abuse Liability study for NKTR-181, our wholly-owned analgesic molecule which has received Fast Track Status from the FDA.  The results clearly demonstrated that drug abusers could not discriminate NKTR-181 from placebo at doses that we know produced analgesia in earlier studies.  We are on track to report high-level results from the Phase 2 efficacy study of NKTR-181 in chronic pain patients this summer.  Finally, we recently completed enrollment in our Phase 3 study of NKTR-102 ahead of schedule.  NKTR-102 is the first long-acting topoisomerase I inhibitor being developed for the treatment of advanced breast cancer and we expect survival data from this pivotal trial next year."

Revenue in the second quarter of 2013 was $33.9 million as compared to $23.7 million in the second quarter of 2012. Year-to-date revenue for 2013 was $56.9 million as compared to $41.6 million in the first half of 2012.  Revenues included non-cash royalty revenue, related to our February 2012 royalty monetization, of $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively, and $3.5 million in both the second quarter and first half of 2012. This non-cash royalty revenue is offset by non-cash inter
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... ST. PAUL, Minn., Oct. 10, 2011 Prime ... met high standards of pharmacy cost transparency, earning ... certification from the HR Policy Association. This is ... certification. TIPPS certification is given annually ...
... 2011 Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced the resignation of ... Officer, due to personal reasons.  Mr. Reinstein,s resignation is ... current fiscal year.  Until that time, he will assist ...
Cached Medicine Technology:Prime Therapeutics Demonstrates Willingness to Show Actual Pharmacy Costs 2Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer 2Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer 3
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... risk of burns from fires and cooking accidents increases ... cautious, an expert says. "Between Thanksgiving and New ... coming in with burns," said Dr. Steven Sandoval, medical ... of Stony Brook University Hospital in New York. ... not careful, could quickly turn tragic," Sandoval said in ...
(Date:12/25/2014)... 25, 2014 AngelWeddingDress.com tries its best ... online realm. Today, the business has introduced its new ... prom dress promotion. , The new prom outfits are ... every dress lover. They are specially designed for 2015. ... dresses should visit its website before Jan. 26, ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... 8 Three in ten California households lack enough income ... released today by United Ways of California. The report ... living in California, specific to each county, for housing, food ... child care and taxes. , The complete report, ...
... 8 What careers are in demand? Job prospects for ... grow much faster than average through the year 2014. In ... fastest growing occupations during this time period! Population growth and ... In addition, as dentists, workloads increase, they are expected to ...
... , PORTLAND, Ore., Dec. 8 ... disruption and carcinogens. , It sounds crazy, but well-intentioned shoppers do it ... than ever about things like the food we eat, the paint we use ... are still at substantial risk from the cosmetic beauty products we use on ...
... Registration is open for the 2010 AIUM Annual Convention ... the United States dedicated to all disciplines of medical ... Diego, California. The 2010 Annual Convention focuses on emerging ... scientists, and manufacturers as ultrasound continues to advance and ...
... has identified a potential personalized treatment target for the most ... issue of Cancer Cell , the research team describes ... with any type of cancer was overexpressed in papillary ... They also found evidence suggesting possible mechanisms by which MAGP2 ...
... oxygen treatment , TUESDAY, Dec. 8 (HealthDay News) ... for cluster headaches, British researchers have found. , People ... per day in bouts that last for weeks or ... sumatriptan, but frequent use of the drug isn,t recommended ...
Cached Medicine News:Health News:New Report Finds That Three in Ten California Households Cannot Afford Basic Needs 2Health News:2010 Will Be a Great Year for a Change! Start a New Career Now! 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4Health News:AIUM gears up for 2010 Annual Convention in San Diego, California 2Health News:Possible ovarian cancer treatment target identified 2Health News:Oxygen Therapy May Relieve Cluster Headache Pain 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: